JP7858629B2 - Fgfr3抗体および使用の方法 - Google Patents
Fgfr3抗体および使用の方法Info
- Publication number
- JP7858629B2 JP7858629B2 JP2023512280A JP2023512280A JP7858629B2 JP 7858629 B2 JP7858629 B2 JP 7858629B2 JP 2023512280 A JP2023512280 A JP 2023512280A JP 2023512280 A JP2023512280 A JP 2023512280A JP 7858629 B2 JP7858629 B2 JP 7858629B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- cdr
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026074915A JP2026126325A (ja) | 2020-08-21 | 2026-04-28 | Fgfr3抗体および使用の方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063068575P | 2020-08-21 | 2020-08-21 | |
| US63/068,575 | 2020-08-21 | ||
| PCT/US2021/046958 WO2022040560A1 (en) | 2020-08-21 | 2021-08-20 | Fgfr3 antibodies and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026074915A Division JP2026126325A (ja) | 2020-08-21 | 2026-04-28 | Fgfr3抗体および使用の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023538098A JP2023538098A (ja) | 2023-09-06 |
| JP2023538098A5 JP2023538098A5 (cg-RX-API-DMAC10.html) | 2024-08-27 |
| JP7858629B2 true JP7858629B2 (ja) | 2026-05-14 |
Family
ID=77774991
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023512280A Active JP7858629B2 (ja) | 2020-08-21 | 2021-08-20 | Fgfr3抗体および使用の方法 |
| JP2026074915A Pending JP2026126325A (ja) | 2020-08-21 | 2026-04-28 | Fgfr3抗体および使用の方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026074915A Pending JP2026126325A (ja) | 2020-08-21 | 2026-04-28 | Fgfr3抗体および使用の方法 |
Country Status (14)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
| CN120456916A (zh) * | 2022-11-14 | 2025-08-08 | 瑞泽恩制药公司 | 抗fgfr3抗体和抗原结合片段及其使用方法 |
| CN121002062A (zh) | 2023-01-13 | 2025-11-21 | 再生元制药公司 | Fgfr3结合分子及其使用方法 |
| KR20250162619A (ko) | 2023-03-20 | 2025-11-18 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | 연골무형성증을 가진 인간 대상에서의 흉요추 변형의 치료 방법 |
| WO2025207944A1 (en) * | 2024-03-29 | 2025-10-02 | Sidewinder Therapeutics, Inc. | Fgfr3-iiib-binding antibodies |
| WO2025240335A1 (en) | 2024-05-13 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005500034A (ja) | 2001-06-20 | 2005-01-06 | プロション バイオテク リミテッド | 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用 |
| US20100003258A1 (en) | 2008-07-01 | 2010-01-07 | Zhigang Weng | Fibroblast growth factor receptor 3 (fgfr3) binding proteins |
| JP2012521759A (ja) | 2009-03-25 | 2012-09-20 | ジェネンテック, インコーポレイテッド | 抗fgfr3抗体およびこれを用いた方法 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991000916A2 (en) | 1989-07-06 | 1991-01-24 | The Regents Of The University Of California | Receptors for fibroblast growth factors |
| DK0646182T3 (da) | 1992-06-18 | 1996-09-16 | Whittier Inst Diabetes & Endoc | Fremgangsmåde til påvisning af neoplastiske sygdomme |
| AU6446194A (en) | 1993-03-17 | 1994-10-11 | Whittier Institute For Diabetes And Endocrinology, The | Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof |
| US6517872B1 (en) | 1995-06-12 | 2003-02-11 | Yeda Research And Development Co., Ltd. | FGFR3 as a marker for mesenchymal skeletal progenitor cells |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| ZA200007412B (en) | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
| US20030143676A1 (en) | 1999-03-25 | 2003-07-31 | Genesis Research And Development Corporation Limited | Fibroblast growth factor receptors and methods for their use |
| EP1208231B2 (en) | 1999-05-05 | 2009-12-30 | Institut Curie | Means for detecting and treating pathologies linked to fgfr3 |
| US7135311B1 (en) | 1999-05-05 | 2006-11-14 | Institut Curie | Means for detecting and treating pathologies linked to FGFR3 |
| AU7764200A (en) | 1999-10-06 | 2001-05-10 | Tigenix N.V. | In vivo assay and molecular markers for testing the phenotypic stability of cellpopulations, and selecting cell populations for autologous transplantation |
| ES2363765T3 (es) | 2002-01-31 | 2011-08-16 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Agonistas de fgfr. |
| NZ537208A (en) | 2002-06-27 | 2009-02-28 | Adipogen Pharmaceuticals Pty Ltd | Differentiation modulating agents and uses therefor |
| AU2003265057A1 (en) | 2002-09-04 | 2004-03-29 | Abtech | Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy |
| CA2510715A1 (en) | 2002-12-20 | 2004-07-08 | Enkam Pharmaceuticals A/S | Method of modulation of interaction between receptor and ligand |
| WO2004074506A2 (en) | 2003-02-13 | 2004-09-02 | Mergen Ltd | Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers |
| US8124331B2 (en) | 2003-03-26 | 2012-02-28 | Progenika Biopharma, S.A. | In vitro method to detect bladder transitional cell carcinoma |
| IL156495A0 (en) | 2003-06-17 | 2004-01-04 | Prochon Biotech Ltd | Use of fgfr3 antagonists for treating t cell mediated diseases |
| WO2005066211A2 (en) | 2003-12-19 | 2005-07-21 | Five Prime Therapeutics, Inc. | Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention |
| EP1544213B1 (en) | 2003-12-19 | 2008-02-20 | Charité - Universitätsmedizin Berlin | Use of ligands of the antigen cd52 for the treatment of solid tumours and bone-related cancerous diseases |
| AU2005216547B2 (en) | 2004-02-24 | 2009-03-12 | Allergan, Inc. | Botulinum toxin screening assays |
| EP1773305A2 (en) | 2004-05-25 | 2007-04-18 | Yale University Corporation | Method for treating skeletal disorders resulting from fgfr malfunction |
| AU2005302083A1 (en) | 2004-11-04 | 2006-05-11 | Fibron Limited | Treatment of B-cell malignancies |
| EP1659175A1 (en) | 2004-11-18 | 2006-05-24 | Institut Curie | Alterations in seborrheic keratoses and their applications |
| ATE423140T1 (de) | 2005-01-05 | 2009-03-15 | F Star Biotech Forsch & Entw | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
| EP1861419B1 (en) | 2005-03-15 | 2011-06-29 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
| NZ565511A (en) | 2005-07-22 | 2011-03-31 | Five Prime Therapeutics Inc | Compositions and methods of treating disease with FGFR fusion proteins |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| JP2009511613A (ja) | 2005-10-17 | 2009-03-19 | エンカム ファーマシューティカルズ アクティーゼルスカブ | 神経細胞接着分子l1のペプチド断片を含む新規fgf受容体結合化合物 |
| WO2007067968A2 (en) | 2005-12-08 | 2007-06-14 | Novartis Ag | Effects of inhibitors of fgfr3 on gene transcription |
| US8101721B2 (en) | 2006-06-15 | 2012-01-24 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
| WO2008127707A1 (en) | 2007-04-13 | 2008-10-23 | Dana Farber Cancer Institute, Inc. | Receptor tyrosine kinase profiling |
| EP2190861A4 (en) | 2007-08-22 | 2011-03-30 | Univ California | ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE |
| ES2553390T3 (es) | 2008-02-25 | 2015-12-09 | Nestec S.A. | Método para la detección de receptores truncados intracelulares |
| WO2009146033A2 (en) | 2008-03-31 | 2009-12-03 | Sma Foundation | Compositions and methods for modulating smn activity |
| KR101590495B1 (ko) | 2008-05-29 | 2016-02-01 | 갤럭시 바이오테크, 엘엘씨 | 염기성 섬유모세포 성장 인자에 대한 모노클로날 항체 |
| AR073770A1 (es) | 2008-10-20 | 2010-12-01 | Imclone Llc | Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden |
| WO2011088196A2 (en) | 2010-01-14 | 2011-07-21 | Yale University | Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof |
| CN105859889B (zh) * | 2010-11-17 | 2020-01-07 | 中外制药株式会社 | 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子 |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| WO2013088191A1 (en) | 2011-12-12 | 2013-06-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3 |
| KR20220017512A (ko) | 2012-03-08 | 2022-02-11 | 아스테라스 세이야쿠 가부시키가이샤 | 신규 fgfr3 융합체 |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| US20150292030A1 (en) | 2012-11-27 | 2015-10-15 | Board Of Regents, The University Of Texas System | Methods of characterizing and treating molecular subset of muscle-invasive bladder cancer |
| CN105209607B (zh) | 2013-04-05 | 2020-02-07 | 大学健康网络 | 产生软骨细胞谱系细胞和/或类软骨组织的方法和组合物 |
| TWI541022B (zh) | 2013-12-18 | 2016-07-11 | 應克隆公司 | 針對纖維母細胞生長因子受體-3(fgfr3)之化合物及治療方法 |
| SG11201706727XA (en) | 2015-02-19 | 2017-09-28 | Bioclin Therapeutics Inc | Methods, compositions, and kits for treatment of cancer |
| CN110785184A (zh) | 2017-02-06 | 2020-02-11 | 雷尼尔医疗公司 | 用于治疗癌症的方法,组合物和试剂盒 |
-
2021
- 2021-08-20 TW TW110130895A patent/TW202229343A/zh unknown
- 2021-08-20 JP JP2023512280A patent/JP7858629B2/ja active Active
- 2021-08-20 IL IL300623A patent/IL300623A/en unknown
- 2021-08-20 US US17/407,774 patent/US11505611B2/en active Active
- 2021-08-20 AR ARP210102356A patent/AR123306A1/es unknown
- 2021-08-20 MX MX2023002106A patent/MX2023002106A/es unknown
- 2021-08-20 KR KR1020237009493A patent/KR20230052963A/ko active Pending
- 2021-08-20 CN CN202180051281.1A patent/CN116323666A/zh active Pending
- 2021-08-20 WO PCT/US2021/046958 patent/WO2022040560A1/en not_active Ceased
- 2021-08-20 BR BR112023002455A patent/BR112023002455A2/pt unknown
- 2021-08-20 EP EP21770357.8A patent/EP4200019A1/en active Pending
- 2021-08-20 AU AU2021327387A patent/AU2021327387A1/en active Pending
- 2021-08-20 CA CA3189470A patent/CA3189470A1/en active Pending
-
2022
- 2022-10-12 US US18/045,995 patent/US20230303704A1/en active Pending
-
2023
- 2023-02-14 CO CONC2023/0001559A patent/CO2023001559A2/es unknown
-
2026
- 2026-04-28 JP JP2026074915A patent/JP2026126325A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005500034A (ja) | 2001-06-20 | 2005-01-06 | プロション バイオテク リミテッド | 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用 |
| US20100003258A1 (en) | 2008-07-01 | 2010-01-07 | Zhigang Weng | Fibroblast growth factor receptor 3 (fgfr3) binding proteins |
| JP2012521759A (ja) | 2009-03-25 | 2012-09-20 | ジェネンテック, インコーポレイテッド | 抗fgfr3抗体およびこれを用いた方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2026126325A (ja) | 2026-08-04 |
| US20220056142A1 (en) | 2022-02-24 |
| EP4200019A1 (en) | 2023-06-28 |
| BR112023002455A2 (pt) | 2023-03-28 |
| CN116323666A (zh) | 2023-06-23 |
| IL300623A (en) | 2023-04-01 |
| WO2022040560A1 (en) | 2022-02-24 |
| AU2021327387A1 (en) | 2023-05-04 |
| AU2021327387A9 (en) | 2023-07-06 |
| TW202229343A (zh) | 2022-08-01 |
| JP2023538098A (ja) | 2023-09-06 |
| KR20230052963A (ko) | 2023-04-20 |
| MX2023002106A (es) | 2023-03-15 |
| AR123306A1 (es) | 2022-11-16 |
| CA3189470A1 (en) | 2022-02-24 |
| CO2023001559A2 (es) | 2023-02-16 |
| US20230303704A1 (en) | 2023-09-28 |
| US11505611B2 (en) | 2022-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7610302B2 (ja) | Ccr8抗体及びその用途 | |
| US20230192835A1 (en) | Optimized anti-tl1a antibodies | |
| US20220220218A1 (en) | Anti-cd73 antibody, antigen-binding fragment thereof and application thereof | |
| US11505611B2 (en) | FGFR3 antibodies and methods of use | |
| CN112969716B (zh) | 抗pd-1抗体、其抗原结合片段及医药用途 | |
| CN114262379B (zh) | 一种pd-1/vegf四价双特异性抗体、其制备方法和用途 | |
| US20240076398A1 (en) | Antibody Molecules to C5AR1 and Uses Thereof | |
| US20240294622A1 (en) | Novel anti-gremlin1 antibodies | |
| JP2024512351A (ja) | Gdf-15に対する抗体 | |
| JP2021515542A (ja) | Pd1結合剤 | |
| CN116323664A (zh) | 抗β细胞素抗体、其片段和多特异性结合分子 | |
| CN112243443B (zh) | 抗trop-2抗体、其抗原结合片段及其医药用途 | |
| JP7633259B2 (ja) | TGF-βRII結合タンパク質 | |
| CN116903744B (zh) | 抗cd73抗体或其抗原片段及其应用 | |
| US20250277038A1 (en) | Anti-pd-l1 antibody and use thereof | |
| RU2807484C2 (ru) | Антитело к pd-1, его антигенсвязывающий фрагмент и его фармацевтическое применение | |
| WO2026072909A2 (en) | Flt1 binding proteins and methods of use | |
| JP2024544386A (ja) | Pd-l1抗原結合タンパク質及びその使用 | |
| HK40065460A (en) | Bispecific antibody and use thereof | |
| HK40036076B (en) | Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240819 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240819 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251014 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260116 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260331 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260428 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7858629 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |